Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
151.23%
-
Total 13F principal
-
$197,728,000
-
Principal change
-
+$770,000
-
Total reported market value
-
$298,513,297
-
Number of holders
-
22
-
Value change
-
+$5,674,200
-
Number of buys
-
11
-
Number of sells
-
12
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q4 2021
As of 31 Dec 2021,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$197,728,000
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, BAKER BROS. ADVISORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), DeepCurrents Investment Group LLC, LAZARD ASSET MANAGEMENT LLC, MACKAY SHIELDS LLC, WELLS FARGO & COMPANY/MN, AMERIPRISE FINANCIAL INC, WELLINGTON MANAGEMENT GROUP LLP, and Verition Fund Management LLC.
This page lists
23
institutional bondholders reporting positions
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.